secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-205129
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Q1 GAAP net loss $125.4M on warrant revaluation; Phase 3 roluperidone trial advances
--------------------------------------------------------------------------------

- Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated; first patient screened March 2026; topline data expected 2H 2027.
- GAAP net loss $125.4M ($2.86/share) vs $3.8M ($0.50) prior year; non-GAAP adjusted net loss $7.3M ($0.17/share).
- Cash and equivalents $78.2M at March 31, down from $82.4M at Dec 31; warrant exercise raised net $1.2M in Q1.
- Leadership: Appointed Jim O’Connor CBO & General Counsel; President Geoff Race left, remains as consultant.
- R&D spend rose to $5.3M from $1.4M on trial costs; G&A $11.4M included $6.6M one-time stock comp charge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/0001193125-26-205129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526205129/d947378d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-205129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer